1. Home
  2. KRNT vs PRTA Comparison

KRNT vs PRTA Comparison

Compare KRNT & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kornit Digital Ltd.

KRNT

Kornit Digital Ltd.

HOLD

Current Price

$16.03

Market Cap

668.4M

Sector

Industrials

ML Signal

HOLD

Logo Prothena Corporation plc

PRTA

Prothena Corporation plc

HOLD

Current Price

$10.73

Market Cap

539.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KRNT
PRTA
Founded
2002
2012
Country
Israel
Ireland
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
668.4M
539.9M
IPO Year
2014
2013

Fundamental Metrics

Financial Performance
Metric
KRNT
PRTA
Price
$16.03
$10.73
Analyst Decision
Buy
Buy
Analyst Count
4
9
Target Price
$19.75
$19.00
AVG Volume (30 Days)
299.3K
419.1K
Earning Date
05-13-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$814,000.00
Revenue This Year
$4.52
$1,111.38
Revenue Next Year
$7.84
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.93
$4.32
52 Week High
$23.48
$11.69

Technical Indicators

Market Signals
Indicator
KRNT
PRTA
Relative Strength Index (RSI) 57.54 60.60
Support Level $14.13 $9.69
Resistance Level $16.33 $10.90
Average True Range (ATR) 0.51 0.35
MACD -0.01 -0.00
Stochastic Oscillator 65.71 70.47

Price Performance

Historical Comparison
KRNT
PRTA

About KRNT Kornit Digital Ltd.

Kornit Digital Ltd develops, designs and markets digital printing solutions for the world-wide printed textile industry. The company focuses on its DTG and DTF segments of the printed textile industry. Its solutions include digital printing systems, ink and other consumables, associated software and value-added services that allow for large-scale printing of short runs of complex images and designs directly on finished garments and fabrics. It generates revenue from sales of systems, ink and other consumables and service including software subscriptions The company geographically operates in U.S., EMEA, Asia Pacific and other countries. It derives maximum revenue from U.S.

About PRTA Prothena Corporation plc

Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.

Share on Social Networks: